OMER Omeros Corp: Net earnings per one share for the last twelve months

This chart of EPS (TTM) quotes for Omeros Corporation (OMER), where the figure stands at 168.70, illustrates the development trajectory of biopharmaceuticals in the field of complement inhibitors. The business relies on a strong staff of neurobiologists who ensure the preservation of key competencies. The scaling model is based on patent law, which guarantees high returns from global sales of therapies for inflammatory brain processes.
OMER (Omeros Corp.): analytical breakdowns and indicator data

Year-over-year EPS growth (TTM) measures the rate of change in earnings per share over twelve months, revealing hidden decelerations in business efficiency. Stagnation of this metric often leads to multiple compression and asset sell-offs. By analyzing the 12-month annual EPS growth trend, an investor assesses the sustainability of profitability. This is critical for Omeros Corporation (OMER), as the company is systematically deploying liquidity to develop clinical programs.